key: cord-1028256-cg7mx0fw
authors: Subir, Ray; Jagat J, Mukherjee; Kalyan K, Gangopadhyay
title: Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19)
date: 2020-07-11
journal: Diabetes Metab Syndr
DOI: 10.1016/j.dsx.2020.07.011
sha: 316ee7629c10cbc5b1445ee8be19b49f48332479
doc_id: 1028256
cord_uid: cg7mx0fw

BACKGROUND AND AIMS: Morbidity and mortality from coronavirus disease 2019 (COVID-19) is higher among people with diabetes mellitus (DM), hypertension, and cardiovascular disease (CVD). Statins are used in the majority of people with DM and CVD. This mini-review discusses the current understanding of benefit-risk ratio of use of statins in COVID-19. METHODS: We searched PubMed database using specific keywords related to our aims till June 12, 2020. Full text of relevant articles published in English language were retrieved and reviewed. RESULTS: Statins, with their immunomodulatory, anti-inflammatory, anti-thrombotic, and anti-oxidant properties, have the potential to reduce severity of lung injury in, and mortality from, severe acute respiratory syndrome-coronavirus 2 (SARS-CoV2) infections. Statin-induced upregulation of angiotensin-converting enzyme-2 (ACE2) has the potential to reduce lung injury from excess angiotensin II. By disrupting lipid rafts, statins have the potential to reduce viral entry into cells. However, benefit-risk ratio of its complex interaction with MYD88 gene expression on outcomes in COVID-19, and the putative role of low serum LDL cholesterol in increasing severity of SARS-CoV2 infection need further clarification. CONCLUSIONS: People with COVID-19, who are already on statins for an underlying co-morbid condition, should continue on it unless there are specific contraindications. De-novo use of statins in people with COVID-19 with no underlying co-morbidity might be beneficial but awaits substantiation in clinical trials; till that time, de novo use of statins in COVID 19 should be limited to a clinical trial setting.

Coronavirus disease 2019 , caused by severe acute respiratory syndromecoronavirus 2 (SARS-CoV2), can lead to multi-organ dysfunction and death in a few; elderly, and those with underlying co-morbidities, are particularly vulnerable. Li et al reported a prevalence of diabetes mellitus (DM), cardiovascular disease (CVD) and hypertension of 9.7%, 16.4% and 17.1% among people hospitalized with COVID-19 [1] . The case fatality rate (CFR) in people with pre-existing DM and CVD was 7.3% and 10%-15% respectively, compared to an overall CFR of 2.3% among 72,314 people with COVID-19 [2] . Among other factors, it has been speculated that some of the medications used in these co-morbidities, namely dipeptidyl peptidase 4 inhibitors, glucagon-like peptide-1 receptor agonists, pioglitazone [3] , angiotensin-converting enzyme inhibitors, angiotensin receptor blockers [4] , and statins [5] , might have an impact on outcome.

Statins, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA), are indicated, and widely used, in the majority of people with DM and CVD, primarily to reduce CVD events by treating hypercholesterolemia. However, statins also have immunomodulatory, antiinflammatory, and anti-thrombotic effects, which has led some to propose their use to improve outcomes in COVID-19 [6] . However, others oppose this concept, suggesting harm [7] . In this article, we briefly review the current understanding of the benefit-risk ratio of use of statins in people with COVID-19. Toll-like receptors (TLR) recognize pathogen-associated molecular patterns on viruses and other pathogens, and together with a set of adapter proteins, activate a signaling cascade that activates nuclear factor-kappa B (NF-kB) to trigger innate immunity. Myeloid differentiation primary response 88 (MyD88) is the main adapter protein for the majority of TLRs [8] .

Statins are known TLR-MyD88 pathway antagonists. They stabilize MyD88 levels during hypoxia and stress, thereby mitigating NF-kB activation [9, 10] . The effect of SARS-CoV2 on TLR-Myd88 pathway is largely unknown. However, extrapolating findings from studies with SARS-CoV, it is postulated that effect of statins on MYD88 gene expression might prevent SARS-CoV2 induced lung injury [5] . Interestingly, despite the many limitations of an observational study, Spigeleer et al. reported that statin intake among 153 elderly people with COVID-19 was significantly associated with absence of symptoms; the effect on long-stay hospitalization or death was positive but did not reach statistical significance (OR 0.75; CI 0.25-1.85) [11] . Overall, the small but significant benefit seen in this small observational study, and the theoretical potential for benefit from the immunomodulatory effects of statins, has already spurred a number of clinical trials to assess the effect of statins on outcomes in people with COVID-19 [12] .

2b. Statins, inflammation, and oxidative stress Statins inhibit HMG-CoA reductase, which blocks the generation of mevalonate, the ratelimiting step in cholesterol synthesis. This results in the lowering of low-density lipoprotein (LDL) cholesterol, which in itself has an anti-inflammatory effect as LDL cholesterol is a strong promoter of inflammation [13] . Moreover, mevalonate is also a precursor of many isoprenoid compounds. Hence statins lead to a depletion of farnesyl pyrophosphate and geranylgeranyl pyrophosphate. This inhibition of prenylation of a variety of important cell-signalling small Gproteins leads to down-regulation of NF-kB, suppression of cytokines and chemokines, with resultant anti-inflammatory effect [14] . Statins reduce the serum concentration of the systemic inflammatory bio-marker C-reactive protein (CRP). The evidence for benefit from these antiinflammatory effects of statins was first realized in people with CVD. In the prospective pravastatin inflammation/CRP evaluation (PRINCE) RCT, pravastatin significantly reduced serum CRP levels at 12 and 24 weeks in subjects with or without CVD, largely independent of changes in LDL cholesterol levels [15] . Similarly, in the landmark JUPITER trial, rosuvastatin significantly reduced major cardiovascular events in healthy persons with LDLC <130 mg/dL and highsensitivity C-reactive protein ≥2 mg/dL [16] . The beneficial anti-inflammatory effects of statins, first noticed in the pathogenesis of atherosclerosis, led to their use in other inflammatory diseases, including rheumatoid arthritis, multiple sclerosis and uveitis [17] .

Statins protect the vascular endothelium from oxidative damage. They increase the expression of endothelial nitric oxide synthase, and suppress pro-oxidant enzymes, such as NADPH oxidase, leading to reduction of reactive oxygen species [18] . By restoring redox balance in the vascular endothelium, statins reduce vascular inflammation triggered by oxidative stress. in one study [19] . Autopsy findings of non-survivors, who had elevated fibrinogen, prothrombin time, and D-dimer at presentation, revealed extensive involvement of peripheral pulmonary vasculature, multiple small thrombi, and oedema/haemorrhage in the lung parenchyma [20] .

Statins have anti-platelet effects; they reduce platelet activation via both lipid-lowering and lipid-independent mechanisms [21] . Moreover, statins also have weak anti-thrombotic activity, which is mediated by a complex mechanism. Statins decrease tissue factor protein/activity, which converts factor X to factor Xa, and tissue plasminogen activator inhibitor-1, and increases the levels of tissue factor pathway inhibitor, thrombomodulin, activated protein C, and tissue plasminogen activator [22] . The theoretical benefit from this weak anti-thrombotic and antiplatelet activity of statins needs confirmation in clinical trials among people with COVID-19. There is low to moderate quality evidence that statin use might decrease the severity of, and mortality from, viral pneumonias, possibly due to its immunomodulatory and anti-inflammatory effects [25] . Interestingly, a recent study, using computational molecular docking method, found that statins are efficient SARS-CoV2 main protease (Mpro) inhibitors [26] . SARS-CoV2

Mpro is a key protein in SARS-CoV2 life cycle; it cuts the polyproteins to yield functional viral proteins. However, more experiments and clinical studies are necessary to confirm this nascent concept of statins directly inhibiting the virus particle.

Keeping in mind the above beneficial effects of statins, several clinical trials have already been designed and registered at clinicaltrials.gov to study the effect of statins, either individually or in combination, on clinically relevant outcomes in people with SARS-CoV2 infection [27] .

Serum total, HDL, and LDL cholesterol levels were significantly lower among 71 people hospitalized for COVID-19 when compared to 80 matched healthy controls [28] . Commenting on this, Ravnskov has suggested that low serum LDL cholesterol predisposes to infections because LDL particles adhere to and inactivate microorganisms and their toxins [7] . The inverse association between serum cholesterol and morbidity and mortality from infectious diseases was separately noted in a meta-analysis of 19 cohort studies including almost 70,000 deaths [29] , and in a 15-year follow-up study of 120,000 adults [30] . Based on these associations, a few researchers have opined that by lowering LDL cholesterol levels, statins can increase morbidity and mortality in people with severe COVID-19 [7] . However, the quality of evidence for a [Type here] [Type here] causative role of low serum total and LDL cholesterol in increasing morbidity/mortality from infectious diseases, and in particular SARS-CoV2 infection, is low, and mostly derived from retrospective analyses of observational data, which are fraught with biases.

3b. Effect of statins on innate immunity and its impact on SARS-CoV2 infection In simplistic terms, the fact that statins are known TLR-MyD88 pathway antagonists, has led some to speculate that use of statins might interfere with innate immune response, and worsen SARS-CoV2 infection. However, as discussed above, the effect of statins on MYD88 gene expression, its role in innate and adaptive immunity, and the effect of such interactions on the severity of viral infection is complex. Moreover, the response might differ depending upon the infecting virus.

Muscle symptoms/toxicity, and liver dysfunction, are the two prominent, albeit rare, adverse effects of statin therapy. Muscle symptoms generally occur within one month of initiation of therapy, with myalgia being reported in 2%-7% of people on statins [31] . People with severe COVID-19 might have skeletal muscle involvement with elevated serum creatine kinase, reported in 19.3% in one series [32] , or frank rhabdomyolysis; it is essential to discontinue statins in people with COVID-19 with skeletal muscle symptoms. Although serious hepatotoxicity is rare, statins cause mild elevation in liver enzymes in 10%, and elevation more than three times the upper limit of normal in 1%-3% of people [33] . Elevated liver enzymes have been recorded in 16%-53% of people with moderate to severe COVID-19 [34] . It is essential to discontinue statin therapy in people with COVID-19 with elevated liver enzymes.

Use of protease inhibitors like lopinavir/ritonavir in COVID-19, which are potent inhibitors of cytochrome P-450 system of enzymes, inhibit the metabolism of most statins, there by significantly increasing their serum levels, with the potential for increased toxicity [35] .

Maximum daily dose of 20 mg for atorvastatin, and 10 mg for rosuvastatin, have been proposed when used together with such protease inhibitors [36] . Rare instances of rhabdomyolysis have been reported due to statin-azithromycin interaction [37] . (Table 1) Most people with T2DM, CVD, and hypertension are on statins. We suggest that people with COVID-19, who are already on a statin for an underlying co-morbid condition, should continue on it because cardiovascular complications, including myocarditis, myocardial infarction and venous thromboembolic events are common in people with COVID-19. Statins should be discontinued if there is myositis and/or liver dysfunction, and their dose must be appropriately reduced when drugs that inhibit cytochrome P-450 system are in use.

De-novo use of statins in people with COVID-19 might be beneficial but needs substantiation.

Theoretically, the pleiotropic properties of statins, including its immunomodulatory, antiinflammatory, anti-thrombotic, and anti-oxidant effects might reduce the severity of SARS-CoV2 infection. Moreover, by inhibiting SARS-CoV2 main protease, statins might have a direct effect on the virus particle. Statins might also have a potential role in reducing viral entry into the cells by interfering with the cholesterol bridges on the cell wall. However, the benefit-risk ratio of its complex interaction with MYD88 gene expression on outcome in COVID-19, and the role of low serum LDL cholesterol on putative increase in severity of COVID-19 needs further clarification.

In balance, although the benefit-risk ratio for use of statins in COVID-19 is in its favor, the unresolved issues, albeit minor, do not allow us to recommend routine de-novo use of statins in all people with COVID-19. Till further evidence from on-going trials is available, it is prudent to use de-novo statins in COVID-19 only in a clinical trial setting. [4, 24] Upregulation of expression of ACE2 Potential to reduce SARS-CoV2 induced lung injury mediated by excess Angiotensin-II SARS-CoV2 main protease [26] Efficient inhibitors of SARS-CoV2 main protease (Computational molecular docking method) Potential to directly inhibit the virus, reducing viral load

and LDL cholesterol levels [7] Reduction of serum total and LDL cholesterol Speculated that this might increase morbidity/mortality from SARS-CoV2 infection, as elevated LDL cholesterol is protective since LDL particles adhere to and inactivate microorganisms and their toxins Immunomodulation [10] Inhibition of MyD88 expression Speculated to reduce innate immunity response, thereby worsening SARS-CoV2 infection Angiotensin converting enzyme 2 (ACE2) [24] Upregulation of expression of ACE2 Potential to increase SARS-CoV2 entry into cells

Myositis and liver dysfunction [31, 32, 33, 34] 1. Mild elevation of liver enzymes in 10%, and elevation >3 times upper limit of normal in 1%-3% 2. Myalgia in 2%-7%

Detrimental effect in people with COVID-19 with skeletal muscle symptoms or liver dysfunction Drug interactions [35, 37] Inhibition of cytochrome P-450 group of enzymes by protease inhibitors used in COVID-19 may significantly increase statin levels Increased risk of toxicity: myopathy and rhabdomyolysis COVID-19: coronavirus disease-19; SARS-CoV2: severe acute respiratory syndrome coronavirus 2; MyD 88: myeloid differentiation primary response 88; NF-kB: nuclear factor kappa-light-chain-enhancer of activated B cells; TNF-α: tumour necrosis factor-α; IL -6, 8 interleukin 6,8; NADPH: nicotinamide adenine dinucleotide phosphate reduced form; ACE: angiotensin converting enzyme; LDL: Low-density lipoprotein cholesterol

Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention

Use of pioglitazone in people with type 2 diabetes mellitus with coronavirus disease 2019 (COVID-19): Boon or bane?

The effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on death and severity of disease in patients with coronavirus disease 2019 (COVID-19): A meta-analysis

Statin therapy in COVID-19 infection

Potential role of statins in COVID-19

Cholesterol-lowering treatment may be a major cause of serious Covid-19 infections

Toll-like receptors are key participants in innate immune responses

Statins may decrease the fatality rate of middle east respiratory syndrome infection

Atorvastatin attenuates myocardial remodeling induced by chronic intermittent hypoxia in rats: partly

The effects of ARBs, ACEIs and statins on clinical outcomes of COVID-19 infection among nursing home residents

Prospective randomized open-label trial of atorvastatin as adjunctive treatment of COVID-19

Does low-density lipoprotein cholesterol induce inflammation? If so, does it matter? Current insights and future perspectives for novel therapies

Evidence for anti-inflammatory activity of statins and PPAR-alpha activators in human C-reactive protein transgenic mice in-vivo and in cultured human hepatocytes in vitro

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

Do statins offer therapeutic potential in inflammatory arthritis?

Statins as regulators of redox state in the vascular endothelium: beyond lipid lowering

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Pulmonary and cardiac pathology in Covid-19: the first autopsy series from New Orleans. medRxiv

Mechanisms for antiplatelet action of statins

Kruppel-like factor 2 (KLF2) regulates endothelial thrombotic function

Importance of cholesterol-rich membrane microdomains in the interaction of the S protein of SARS-coronavirus with the cellular receptor angiotensin-converting enzyme 2

Effects of rosuvastatin on expression of angiotensinconverting enzyme 2 after vascular balloon injury in rats

Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins

Statins and the COVID-19 main protease: in silico evidence on direct interaction

Statin therapy and COVID-19 infection (STACOV PROJECT)

Low serum cholesterol level among patients with COVID-19 infection in Wenzhou

Report of the conference on low blood cholesterol: Mortality associations

Cohort study of serum total cholesterol and inhospital incidence of infectious diseases

Statin-induced myopathies

Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China

The liver and lovastatin

The liver in times of COVID-19: What hepatologists should know

Statin toxicity -mechanistic insights and clinical implications

Liverpool COVID-19 drug interactions

Highlights: • Statins have many pleiotropic properties that can potentially reduce morbidity and mortality

People with coronavirus disease-19 who are already on a statin should continue on it unless there is a contraindication. • Pending further evidence, de-novo use of statins in coronavirus disease-19 should be limited to a clinical trial setting